Verve Therapeutics, a Cambridge biotech that wants to use gene-editing to lower cholesterol, said Thursday that it has raised $63 million in venture capital to advance an experimental approach to fighting heart disease.
The company raised $60 million in venture capital in its first fundraising effort less than two years ago. Verve was officially launched in May 2019 and has financial backing from a number of well-known venture capitalists, including GV, formerly Google Ventures.
